Expression of c-Myc and p53 Correlates With Clinical Outcome in Diffuse Large B-Cell Lymphomas
Open Access
- 1 April 2000
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 113 (4), 512-518
- https://doi.org/10.1309/yhfe-r65b-d3lk-3ggv
Abstract
We performed a retrospective immunohistochemical study of the relationships between clinical manifestations and outcomes of diffuse large B-cell lympKeywords
This publication has 24 references indexed in Scilit:
- Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.Journal of Clinical Oncology, 1998
- Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: Clinical relevance in 71 patientsAnnals of Oncology, 1998
- Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.Journal of Clinical Oncology, 1996
- Rearrangement of the bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell LymphomaNew England Journal of Medicine, 1994
- Identification of genetic lesions associated with diffuse large-cell lymphomaAnnals of Oncology, 1994
- Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases.Journal of Clinical Oncology, 1994
- bcl-2 Rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical featuresCancer, 1993
- The Association of c-myc Rearrangements with Specific Types of Human Non-Hodgkin's LymphomasLeukemia & Lymphoma, 1992
- 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significanceBritish Journal of Haematology, 1989
- bcl-2and Other Genomic Alterations in the Prognosis of Large-Cell LymphomaNew England Journal of Medicine, 1989